| Literature DB >> 31388258 |
Tsvetelina Kostadinova1, Liliya Ivanova Ivanova2,3, Tatina Todorova Todorova4, Zhivka Stoykova2,3, Dobromir Staykov5, Merlin Efraim6, Liana Gercheva6.
Abstract
Epstein-Barr virus is the first human oncogenic virus associated with a broad range of different malignant diseases but its role in non-Hodgkin lymphomas (NHL) development still needs to be fully understood. High expression levels of EBV major genes are found in NHL tumor cells and free viral DNA circulates in the plasma of such individuals. In the current study we detected EBV DNA levels in plasma samples from NHL patients in order to validate its significance as a laboratory marker for disease monitoring. We investigated a cohort of 52 patients diagnosed with NHL in The University Hospital "St. Marina" Varna, Bulgaria. Viral DNA was extracted from single plasma samples using Kit Ribo Virus (Sacace Biotechnologies S.r.l., Como, Italy) and amplified with EBV Real-TM Quant (Sacace Biotechnologies S.r.l., Como, Italy). Plasma samples of the same patients were tested for presence of EBV VCA IgM/IgG antibodies with indirect ELISA tests (Euroimmun, Luebeck, Germany). We found 15.4% (95% CI 6.9-28.1%, n = 8) of the samples from NHL patients to be positive in quantitative PCR (range 674-221,333 copies/ml). The diffuse large B cell lymphomas and peripheral T cell lymphomas were most often associated (although not statistically significant, p = 0.167) with detectable plasma EBV DNA levels. To our knowledge, this is the first study about the role of EBV in NHL development in Bulgaria. The results we have obtained should stimulate new, larger investigations to apply the quantitative PCR technique in the routine laboratory EBV diagnosis.Entities:
Keywords: EBV DNA; Epstein–Barr virus; Non-Hodgkin lymphoma
Year: 2019 PMID: 31388258 PMCID: PMC6646448 DOI: 10.1007/s12288-019-01088-8
Source DB: PubMed Journal: Indian J Hematol Blood Transfus ISSN: 0971-4502 Impact factor: 0.900